Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Phase 2 Unknown 59 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma

Timeline

Start: 2021-03-20
Primary completion: 2023-03-20
Completion: 2025-03-20

Publications

Wang Z, Sun Y, Wang Q, Chai Y, Sun J, Zhang X, Wang Q, Wang W, Wang P. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China. BMC Med. 2025 Feb 27;23(1):126. doi: 10.1186/s12916-025-03964-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	—
Subject	Cisplatin	Other / unclassified	20 mg/m2	—
Subject	Cisplatin	Other / unclassified	75 mg/m2	—
Subject	Cisplatin	Other / unclassified	80 mg/m2	—
Subject	Docetaxel	Small molecule	75 mg/m2	—

Indications

No indication recorded.